Innovative Pre-Clinical Data Using Peptides to Intervene in the Evolution of Pulmonary Fibrosis
Karina Smidt Simon1, Luísa Coutinho Coelho1, Paulo Henrique de Holanda Veloso1
1Department of Cellular Biology, Institute of Biological Sciences, University of Brasilia, Brasilia 70910-900, Brazil.
International Journal of Molecular Sciences
|July 14, 2023
Summary
New immunomodulatory peptides, ToAP3 and ToAP4, show promise in controlling experimental idiopathic pulmonary fibrosis (IPF). These peptides helped maintain lung tissue characteristics and function in a mouse model, offering potential new therapies for IPF.
Area of Science:
- Pulmonary Medicine
- Immunology
- Pharmacology
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with poorly understood mechanisms, hindering effective treatment development.
- Current therapeutic options for IPF are limited, emphasizing the need for novel treatment strategies.
Purpose of the Study:
- To investigate the potential of immunomodulatory peptides, specifically ToAP3 and ToAP4, as a therapeutic alternative for chronic pulmonary fibrosis.
- To evaluate the efficacy of ToAP3 and ToAP4 in a bleomycin (BLM)-induced pulmonary fibrosis mouse model.
Main Methods:
- A chronic pulmonary fibrosis model was established in BALB/c mice using intratracheal bleomycin (BLM) instillation.
- Mice were treated with ToAP3 and ToAP4 peptides starting on day 5 post-BLM instillation, with analyses performed on day 30.
- Evaluations included ELISA, qPCR, morphological assessment, and respiratory function tests.
Main Results:
- ToAP3 and ToAP4 treatments delayed the inflammatory and fibrotic processes induced by BLM.
- Peptide treatment mitigated alterations in collagen I, III, and IV production and preserved ventilatory mechanics.
- Gene expression patterns indicated distinct mechanisms of action for ToAP3 and ToAP4, with both peptides regulating fibrotic-associated cytokine production.
Conclusions:
- Immunomodulatory peptides ToAP3 and ToAP4 effectively controlled experimental IPF in a murine model.
- These peptides maintained lung tissue integrity and function while regulating key fibrotic pathways.
- ToAP3 and ToAP4 represent potential therapeutic alternatives or adjuvants for managing idiopathic pulmonary fibrosis.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202